ProfileGDS5678 / 1426049_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 75% 74% 74% 73% 74% 75% 76% 74% 74% 74% 78% 74% 76% 74% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.9285375
GSM967853U87-EV human glioblastoma xenograft - Control 24.8857774
GSM967854U87-EV human glioblastoma xenograft - Control 34.885874
GSM967855U87-EV human glioblastoma xenograft - Control 44.833573
GSM967856U87-EV human glioblastoma xenograft - Control 54.8341674
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.8770975
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9812576
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7966774
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.8753674
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.8843174
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.3807178
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.8792274
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.1411876
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.8735474